Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ORKA

Oruka Therapeutics Inc

Apr 28 • 04:00PM ET

73.99

-2.40 -3.14 %

Healthcare • Biotechnology • USA • Mid • NASD

Apr 28, 7:45 PMOruka Therapeutics announces the pricing of an upsized $700 million underwritten public offering of 9.66 million common shares at $72.50 per share.

Held by: IWM VTI XBI IWN IBB VXF SCHA VTWO IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.32	Insider Own	15.93%	Shs Outstand	48.72M	Perf Week	7.23%
Market Cap	3.71B	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-0.72%	Shs Float	41.65M	Perf Month	66.34%
Enterprise Value	3.38B	PEG	-	EPS next Q	-0.55	Inst Own	95.00%	Short Float	13.30%	Perf Quarter	112.01%
Income	-105.43M	P/S	-	EPS this Y	-23.43%	Inst Trans	17.15%	Short Ratio	6.17	Perf Half Y	171.52%
Sales	0.00M	P/B	7.69	EPS next Y	-18.34%	ROA	-23.84%	Short Interest	5.54M	Perf YTD	144.11%
Book/sh	9.63	P/C	11.02	EPS next 5Y	-20.22%	ROE	-24.69%	52W High	91.00 -18.69%	Perf Year	619.75%
Cash/sh	6.71	P/FCF	-	EPS past 3/5Y	34.61% 37.79%	ROIC	-22.28%	52W Low	8.91 730.42%	Perf 3Y	473.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.29% 7.26%	Perf 5Y	219.34%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	63.93%	Oper. Margin	-	ATR (14)	5.25	Perf 10Y	-84.16%
Dividend Ex-Date	-	Quick Ratio	22.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.09	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	22.37	EPS Q/Q	15.38%	SMA20	15.64%	Beta	-0.13	Target Price	136.62
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	55.05%	Rel Volume	3.44	Prev Close	76.39
Employees	68	LT Debt/Eq	0.00	Earnings	Mar 12 AMC	SMA200	147.62%	Avg Volume	897.15K	Price	73.99
IPO	Aug 08, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.26% -	Trades		Volume	2,954,688	Change	-3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Piper Sandler	Overweight	$75
Nov-13-25	Initiated	Jefferies	Buy	$45
Oct-27-25	Initiated	Guggenheim	Buy	$60
Oct-13-25	Initiated	Barclays	Overweight	$48
May-22-25	Initiated	BTIG Research	Buy	$44
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Show Previous Ratings

Apr-28-26 07:42PM	Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering (GlobeNewswire)
Apr-27-26 04:17PM	Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering (GlobeNewswire) +10.66%
10:24AM	Oruka Therapeutics psoriasis drug clears skin in 64% of patients (Quartz)
09:49AM	Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results (InvestorsHub)
08:12AM	Oruka surges as long-acting psoriasis drug shows early promise (BioPharma Dive)
07:01AM	Loading…
07:01AM	How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise (Investor's Business Daily)
07:00AM	Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Apr-26-26 12:00PM	Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 (GlobeNewswire)
Apr-10-26 05:28PM	This Startup's Psoriasis Drug Studies Have Lifted Its Stock (Barrons.com) -6.32%
Mar-12-26 04:05PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.03% +25.04%
Feb-09-26 07:00AM	Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
Jan-12-26 07:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 (GlobeNewswire) +10.16%
Jan-06-26 07:00AM	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 04:01PM	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire)
Nov-12-25 04:05PM	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
09:55AM	Loading…
Oct-29-25 09:55AM	Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know (Zacks)
07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Sep-29-25 04:24PM	MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment (Investor's Business Daily) +26.91%
Sep-17-25 04:11PM	Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker (Investor's Business Daily) +8.79%
01:02AM	Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire)
01:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire)
Aug-11-25 04:04PM	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.90%
Jul-21-25 07:00AM	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire) -5.30%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire) +5.26% +6.86%
May-27-25 03:32PM	H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial (Insider Monkey)
May-21-25 07:00AM	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire)
May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
08:30AM	Loading…
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-21 04:05PM	Christopher Graybill Joins ARCA as Vice President, Clinical Development (GlobeNewswire)
May-03-21 04:30PM	ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer (GlobeNewswire)

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Option Exercise	7.32	7,000	51,240	40,377	Apr 15 06:45 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Sale	66.12	7,000	462,830	33,377	Apr 15 06:45 PM
JOANA GONCALVES	Officer	Apr 15 '26	Proposed Sale	67.06	21,000	1,408,260		Apr 15 04:54 PM
Klein Lawrence Otto	Chief Executive Officer	Mar 16 '26	Sale	41.30	1,729	71,408	927,309	Mar 17 04:10 PM
Agarwal Arjun	Senior Vice President, Finance	Mar 16 '26	Sale	41.30	395	16,313	18,863	Mar 17 04:09 PM
Sandler Laura Lee	Chief Operating Officer	Mar 16 '26	Sale	41.30	600	24,780	236,984	Mar 17 04:08 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Option Exercise	7.32	7,000	51,240	41,018	Mar 17 04:06 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Sale	40.91	7,641	312,560	33,377	Mar 17 04:06 PM
Quinlan Paul T	General Counsel	Mar 16 '26	Sale	41.30	733	30,273	31,767	Mar 17 04:04 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Option Exercise	7.80	5,000	39,000	242,584	Mar 02 06:47 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Sale	33.56	5,000	167,822	237,584	Mar 02 06:47 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Option Exercise	7.32	7,000	51,240	41,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Sale	32.37	7,000	226,559	34,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Option Exercise	7.32	7,000	51,240	8,518	Jan 16 05:26 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Sale	31.81	7,000	222,704	1,518	Jan 16 05:26 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Option Exercise	7.80	5,000	39,000	218,084	Jan 02 08:25 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Sale	28.52	13,000	370,795	205,084	Jan 02 08:25 PM
LAURA SANDLER	Officer	Jan 02 '26	Proposed Sale	30.31	18,000	545,580		Jan 02 04:31 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Option Exercise	7.32	7,000	51,240	8,518	Dec 19 05:38 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Sale	30.61	7,000	214,293	1,518	Dec 19 05:38 PM
JOANA GONCALVES	Officer	Dec 19 '25	Proposed Sale	28.15	28,000	788,200		Dec 19 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORKA

Oruka Therapeutics Inc

Upgrade your Finviz experience